Long Mary C, Shaddix Sue C, Moukha-Chafiq Omar, Maddry Joseph A, Nagy Lisa, Parker William B
Department of Pharmacology and Toxicology, University of Alabama at Birmingham, AL, United States.
Biochem Pharmacol. 2008 Apr 15;75(8):1588-600. doi: 10.1016/j.bcp.2008.01.007. Epub 2008 Feb 2.
Adenosine kinase (Ado kinase) from Mycobacterium tuberculosis is structurally and biochemically unique from other known Ado kinases. This purine salvage enzyme catalyzes the first step in the conversion of the adenosine analog, 2-methyl-Ado (methyl-Ado), into a metabolite with antitubercular activity. Methyl-Ado has provided proof of concept that the purine salvage pathway from M. tuberculosis may be utilized for the development of antitubercular compounds with novel mechanisms of action. In order to utilize this enzyme, it is necessary to understand the topography of the active site to rationally design compounds that are more potent and selective substrates for Ado kinase. A previous structure-activity relationship identified modifications to the base moiety of adenosine (Ado) that result in substrate and inhibitor activity. In an extension of that work, 62 Ado analogs with modifications to the ribofuranosyl moiety, modifications to the base and ribofuranosyl moiety, or modifications to the glycosidic bond position have been analyzed as substrates and inhibitors of M. tuberculosis Ado kinase. A subset of these compounds was further analyzed in human Ado kinase for the sake of comparison. Although no modifications to the ribose moiety resulted in compounds as active as Ado, the best substrates identified were carbocyclic-Ado, 8-aza-carbocyclic-Ado, and 9-[alpha-l-lyxofuranosyl]-adenine with 38%, 4.3%, and 3.8% of the activity of Ado, respectively. The most potent inhibitor identified, 5'-amino-5'-deoxy-Ado, had a K(i)=0.8muM and a competitive mode of inhibition. MIC studies demonstrated that poor substrates could still have potent antitubercular activity.
来自结核分枝杆菌的腺苷激酶(Ado激酶)在结构和生化性质上与其他已知的Ado激酶不同。这种嘌呤补救酶催化腺苷类似物2-甲基-Ado(甲基-Ado)转化为具有抗结核活性的代谢物的第一步。甲基-Ado已提供概念验证,即结核分枝杆菌的嘌呤补救途径可用于开发具有新型作用机制的抗结核化合物。为了利用这种酶,有必要了解活性位点的拓扑结构,以便合理设计出对Ado激酶而言更有效且更具选择性的底物的化合物。先前的构效关系研究确定了对腺苷(Ado)碱基部分的修饰可产生底物和抑制剂活性。在该研究工作的扩展中,已分析了62种对呋喃核糖基部分进行修饰、对碱基和呋喃核糖基部分进行修饰或对糖苷键位置进行修饰的Ado类似物作为结核分枝杆菌Ado激酶的底物和抑制剂。为作比较,还对其中一部分化合物在人Ado激酶中进行了进一步分析。尽管对核糖部分的修饰未产生与Ado活性相当的化合物,但所确定的最佳底物为碳环-Ado、8-氮杂碳环-Ado和9-[α-L-来苏呋喃糖基]-腺嘌呤,其活性分别为Ado的38%、4.3%和3.8%。所确定的最有效抑制剂5'-氨基-5'-脱氧-Ado的K(i)=0.8μM,抑制模式为竞争性抑制。MIC研究表明,差的底物仍可能具有强大的抗结核活性。